Interpace Diagnostics Group Inc Share Price Nasdaq
Equities
US46062X1054
Managed Healthcare
End-of-day quote
Other stock markets
|
||
- USD | - |
09/05 | Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
07/03 | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M | MT |
Sales 2022 | 3.18Cr 265.15Cr | Sales 2023 | 4.02Cr 334.91Cr | Capitalization | 46.93L 39Cr |
---|---|---|---|---|---|
Net income 2022 | -2.2Cr -183.22Cr | Net income 2023 | - 0 | EV / Sales 2022 | 0.49 x |
Net Debt 2022 | 1.13Cr 94Cr | Net Debt 2023 | 76.94L 64Cr | EV / Sales 2023 | 0.31 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
6.03
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.94% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Burnell
CEO | Chief Executive Officer | 62 | 01/20/01 |
Director of Finance/CFO | 32 | 01/19/01 | |
Nicole Massoll
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Vijay Aggarwal
BRD | Director/Board Member | 75 | 01/22/01 |
Joseph Keegan
BRD | Director/Board Member | 71 | 01/16/01 |
Stephen Sullivan
BRD | Director/Board Member | 77 | 01/04/01 |
1st Jan change | Capi. | |
---|---|---|
-6.74% | 603.51Cr | |
-2.24% | 121.38Cr |